H&H Bio absorbs Humic to build integrated preclinical CRO
What's the deal? HCTDealroom has a profile for this one. Try Dealroom →, a Korean testing, certification, and calibration company, said on 7 August 2026 that its subsidiary H&H BioDealroom has a profile for this one. Try Dealroom → has completed its absorption merger of HumicDealroom has a profile for this one. Try Dealroom →, a preclinical efficacy-testing firm. H&H Bio is the surviving entity and Humic the dissolving one, with HCT keeping its position as largest shareholder.
What's the endgame? The two companies previously collaborated separately on toxicity testing and efficacy evaluation. Combined, they aim to offer an integrated preclinical contract research organisation (CRO) service spanning early-stage efficacy assessment through toxicity testing.
Why now? Both businesses are showing improving numbers. Humic posted revenue of 3.6 billion won and net profit of 400 million won in 2025, while H&H Bio's revenue rose from 1.8 billion won in 2024 to 2.2 billion won in 2025.
H&H Bio's first-quarter revenue jumped 466% year-on-year to 1.3 billion won as previously booked preclinical contracts began generating sales, narrowing its operating loss.
What's the rationale? Humic brings efficacy testing using humanised mouse models and pathology AI analysis, built by researchers from first-generation biotech firms. HCT expects Humic's results to boost H&H Bio's top-line growth and profitability.
The signal: The merger reflects a push to build a single value chain covering both efficacy and toxicity testing. As one H&H Bio official put it, clients can cut development timelines and management costs, while the firm aims to expand "package" orders. HCT said it plans to accelerate its bio unit's path to break-even and develop H&H Bio into a mid-to-long-term growth pillar.
Read more: eDaily
Image credit: IAEA Imagebank
